MKI67 and glioblastoma: Methylation levels of CpGs 72–83 in the MGMT promoter (Figure 4d), CpGs 12–19 of enhancer 1 (Figure 4e), and CpGs 05–08 and CpGs 37–39 of enhancer 2 (Figure 4f) were significantly higher in GBM patients with high Ki-67 index (>50%) compared to those with low (≤50%) Ki-67 index.